Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA070873-01
Application #
2114663
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1996-07-01
Project End
1999-06-30
Budget Start
1996-07-01
Budget End
1997-06-30
Support Year
1
Fiscal Year
1996
Total Cost
Indirect Cost
Name
University of Toledo
Department
Biochemistry
Type
Schools of Medicine
DUNS #
807418939
City
Toledo
State
OH
Country
United States
Zip Code
43614
Elnakat, Hala; Ratnam, Manohar (2004) Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 56:1067-84
Hao, Hong; Qi, Huiling; Ratnam, Manohar (2003) Modulation of the folate receptor type beta gene by coordinate actions of retinoic acid receptors at activator Sp1/ets and repressor AP-1 sites. Blood 101:4551-60
Kelley, Karen M M; Rowan, Brian G; Ratnam, Manohar (2003) Modulation of the folate receptor alpha gene by the estrogen receptor: mechanism and implications in tumor targeting. Cancer Res 63:2820-8
Zheng, Xuan; Kelley, Karen; Elnakat, Hala et al. (2003) mRNA instability in the nucleus due to a novel open reading frame element is a major determinant of the narrow tissue specificity of folate receptor alpha. Mol Cell Biol 23:2202-12
Pan, Xing Q; Zheng, Xuan; Shi, Guangfeng et al. (2002) Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood 100:594-602
Wang, H; Zheng, X; Behm, F G et al. (2000) Differentiation-independent retinoid induction of folate receptor type beta, a potential tumor target in myeloid leukemia. Blood 96:3529-36
Ross, J F; Wang, H; Behm, F G et al. (1999) Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer 85:348-57
Wu, M; Gunning, W; Ratnam, M (1999) Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomarkers Prev 8:775-82